Concepts (154)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| HIV Infections | 26 | 2023 | 791 | 5.300 |
Why?
|
| Viral Load | 9 | 2022 | 127 | 2.190 |
Why?
|
| Antiretroviral Therapy, Highly Active | 3 | 2016 | 73 | 1.180 |
Why?
|
| South Carolina | 20 | 2023 | 2752 | 1.050 |
Why?
|
| CD4 Lymphocyte Count | 6 | 2018 | 98 | 1.050 |
Why?
|
| Rural Health | 2 | 2015 | 66 | 0.930 |
Why?
|
| Health Status Disparities | 4 | 2022 | 326 | 0.850 |
Why?
|
| Pyrrolidinones | 2 | 2012 | 15 | 0.830 |
Why?
|
| HIV Integrase Inhibitors | 2 | 2012 | 12 | 0.820 |
Why?
|
| Continuity of Patient Care | 3 | 2021 | 170 | 0.790 |
Why?
|
| Acquired Immunodeficiency Syndrome | 3 | 2022 | 123 | 0.790 |
Why?
|
| Residence Characteristics | 4 | 2020 | 252 | 0.780 |
Why?
|
| Anti-HIV Agents | 3 | 2020 | 135 | 0.740 |
Why?
|
| Anti-Bacterial Agents | 5 | 2022 | 1026 | 0.740 |
Why?
|
| Social Work | 1 | 2020 | 27 | 0.720 |
Why?
|
| Geriatrics | 1 | 2020 | 69 | 0.700 |
Why?
|
| HIV-1 | 3 | 2018 | 177 | 0.670 |
Why?
|
| Drug Resistance, Bacterial | 1 | 2020 | 98 | 0.670 |
Why?
|
| Resilience, Psychological | 1 | 2019 | 43 | 0.650 |
Why?
|
| Delayed Diagnosis | 1 | 2018 | 39 | 0.620 |
Why?
|
| Patient Acceptance of Health Care | 2 | 2019 | 468 | 0.610 |
Why?
|
| Population Surveillance | 3 | 2019 | 285 | 0.610 |
Why?
|
| Health Personnel | 1 | 2020 | 286 | 0.570 |
Why?
|
| Healthcare Disparities | 2 | 2021 | 378 | 0.570 |
Why?
|
| Socioeconomic Factors | 5 | 2020 | 955 | 0.570 |
Why?
|
| Vascular Access Devices | 1 | 2016 | 21 | 0.560 |
Why?
|
| Nontuberculous Mycobacteria | 1 | 2016 | 22 | 0.560 |
Why?
|
| Catheter-Related Infections | 1 | 2016 | 43 | 0.550 |
Why?
|
| Mycobacterium Infections, Nontuberculous | 1 | 2016 | 37 | 0.540 |
Why?
|
| Pandemics | 5 | 2021 | 352 | 0.510 |
Why?
|
| Quality of Life | 3 | 2021 | 1515 | 0.500 |
Why?
|
| Urban Health | 1 | 2015 | 49 | 0.490 |
Why?
|
| Humans | 38 | 2023 | 68618 | 0.490 |
Why?
|
| Bacteremia | 1 | 2016 | 155 | 0.480 |
Why?
|
| Anti-Retroviral Agents | 3 | 2021 | 53 | 0.470 |
Why?
|
| Adult | 15 | 2022 | 21403 | 0.450 |
Why?
|
| Osteomyelitis | 1 | 2014 | 40 | 0.450 |
Why?
|
| Spinal Diseases | 1 | 2014 | 53 | 0.450 |
Why?
|
| Adolescent | 10 | 2021 | 8912 | 0.430 |
Why?
|
| Anemia, Sickle Cell | 1 | 2016 | 364 | 0.430 |
Why?
|
| Heterocyclic Compounds, 3-Ring | 1 | 2012 | 11 | 0.420 |
Why?
|
| Quinolones | 1 | 2012 | 60 | 0.400 |
Why?
|
| Clostridium Infections | 3 | 2021 | 52 | 0.390 |
Why?
|
| Disease Progression | 1 | 2015 | 1038 | 0.390 |
Why?
|
| Aged | 11 | 2022 | 14862 | 0.370 |
Why?
|
| Female | 16 | 2020 | 38074 | 0.370 |
Why?
|
| Disease Outbreaks | 2 | 2021 | 83 | 0.360 |
Why?
|
| Qualitative Research | 3 | 2021 | 369 | 0.350 |
Why?
|
| Male | 16 | 2021 | 37321 | 0.350 |
Why?
|
| Middle Aged | 11 | 2019 | 21147 | 0.330 |
Why?
|
| Cross Infection | 2 | 2021 | 195 | 0.330 |
Why?
|
| Aged, 80 and over | 5 | 2020 | 4848 | 0.320 |
Why?
|
| Interviews as Topic | 2 | 2020 | 392 | 0.320 |
Why?
|
| Young Adult | 7 | 2020 | 5717 | 0.300 |
Why?
|
| Health Services Accessibility | 2 | 2021 | 581 | 0.260 |
Why?
|
| Treatment Outcome | 4 | 2016 | 7029 | 0.230 |
Why?
|
| Retrospective Studies | 6 | 2022 | 7277 | 0.230 |
Why?
|
| Electronic Health Records | 3 | 2022 | 374 | 0.220 |
Why?
|
| Sexual and Gender Minorities | 2 | 2021 | 44 | 0.210 |
Why?
|
| Coinfection | 1 | 2022 | 30 | 0.210 |
Why?
|
| Raltegravir Potassium | 2 | 2012 | 6 | 0.210 |
Why?
|
| Comorbidity | 3 | 2022 | 1426 | 0.210 |
Why?
|
| Influenza Vaccines | 1 | 2022 | 56 | 0.200 |
Why?
|
| Drug Utilization Review | 1 | 2021 | 19 | 0.200 |
Why?
|
| Influenza, Human | 1 | 2022 | 79 | 0.200 |
Why?
|
| Epidemics | 1 | 2021 | 12 | 0.190 |
Why?
|
| Population Dynamics | 1 | 2021 | 30 | 0.190 |
Why?
|
| Spatio-Temporal Analysis | 1 | 2021 | 28 | 0.190 |
Why?
|
| Travel | 1 | 2021 | 38 | 0.190 |
Why?
|
| Public Health | 1 | 2023 | 201 | 0.190 |
Why?
|
| Drug Resistance, Microbial | 1 | 2020 | 70 | 0.180 |
Why?
|
| Grounded Theory | 1 | 2020 | 20 | 0.180 |
Why?
|
| Social Isolation | 1 | 2020 | 40 | 0.180 |
Why?
|
| Social Media | 1 | 2021 | 59 | 0.170 |
Why?
|
| Forecasting | 1 | 2021 | 277 | 0.170 |
Why?
|
| Vulnerable Populations | 1 | 2020 | 84 | 0.170 |
Why?
|
| Microbial Sensitivity Tests | 1 | 2020 | 226 | 0.170 |
Why?
|
| Sex Offenses | 1 | 2021 | 170 | 0.170 |
Why?
|
| Incidence | 3 | 2022 | 1603 | 0.170 |
Why?
|
| Perception | 1 | 2020 | 189 | 0.160 |
Why?
|
| Healthcare Financing | 1 | 2018 | 3 | 0.160 |
Why?
|
| Insurance Coverage | 1 | 2019 | 99 | 0.160 |
Why?
|
| Activities of Daily Living | 1 | 2020 | 319 | 0.160 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2018 | 106 | 0.150 |
Why?
|
| Time Factors | 2 | 2016 | 4655 | 0.140 |
Why?
|
| Rural Population | 2 | 2017 | 398 | 0.140 |
Why?
|
| Mental Disorders | 1 | 2022 | 659 | 0.140 |
Why?
|
| Social Support | 1 | 2019 | 423 | 0.140 |
Why?
|
| HIV | 1 | 2016 | 56 | 0.130 |
Why?
|
| Cost-Benefit Analysis | 1 | 2018 | 504 | 0.130 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2020 | 504 | 0.130 |
Why?
|
| Urban Population | 1 | 2016 | 255 | 0.130 |
Why?
|
| Disease Notification | 1 | 2015 | 7 | 0.130 |
Why?
|
| Logistic Models | 2 | 2019 | 1420 | 0.130 |
Why?
|
| RNA, Viral | 1 | 2015 | 93 | 0.120 |
Why?
|
| Sex Distribution | 1 | 2015 | 274 | 0.120 |
Why?
|
| Age Distribution | 1 | 2015 | 320 | 0.120 |
Why?
|
| Hospitalization | 1 | 2019 | 978 | 0.110 |
Why?
|
| Telemedicine | 1 | 2021 | 700 | 0.110 |
Why?
|
| Cohort Studies | 4 | 2022 | 2358 | 0.110 |
Why?
|
| Case-Control Studies | 1 | 2016 | 1553 | 0.110 |
Why?
|
| Oxazines | 1 | 2012 | 10 | 0.110 |
Why?
|
| Emtricitabine | 1 | 2012 | 5 | 0.100 |
Why?
|
| Bacteria | 1 | 2014 | 193 | 0.100 |
Why?
|
| Tenofovir | 1 | 2012 | 10 | 0.100 |
Why?
|
| Organophosphonates | 1 | 2012 | 16 | 0.100 |
Why?
|
| Pyridones | 1 | 2012 | 40 | 0.100 |
Why?
|
| Adenine | 1 | 2012 | 46 | 0.100 |
Why?
|
| Biopsy | 1 | 2014 | 540 | 0.100 |
Why?
|
| Deoxycytidine | 1 | 2012 | 83 | 0.100 |
Why?
|
| Prevalence | 1 | 2015 | 1619 | 0.090 |
Why?
|
| Piperazines | 1 | 2012 | 206 | 0.090 |
Why?
|
| Prescriptions | 2 | 2020 | 28 | 0.090 |
Why?
|
| Risk Assessment | 1 | 2016 | 2007 | 0.090 |
Why?
|
| Drug Therapy, Combination | 1 | 2012 | 649 | 0.090 |
Why?
|
| Child | 4 | 2022 | 6405 | 0.090 |
Why?
|
| United States | 5 | 2022 | 7367 | 0.090 |
Why?
|
| Longitudinal Studies | 2 | 2023 | 1054 | 0.080 |
Why?
|
| International Classification of Diseases | 1 | 2006 | 85 | 0.070 |
Why?
|
| HIV Seropositivity | 1 | 2006 | 66 | 0.070 |
Why?
|
| Cross-Sectional Studies | 2 | 2020 | 2279 | 0.060 |
Why?
|
| Knowledge Bases | 1 | 2022 | 3 | 0.050 |
Why?
|
| Preexisting Condition Coverage | 1 | 2022 | 4 | 0.050 |
Why?
|
| Vaccination Coverage | 1 | 2022 | 7 | 0.050 |
Why?
|
| Data Mining | 1 | 2022 | 45 | 0.050 |
Why?
|
| Zambia | 1 | 2021 | 8 | 0.050 |
Why?
|
| Antimicrobial Stewardship | 1 | 2021 | 33 | 0.050 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 1 | 2021 | 92 | 0.050 |
Why?
|
| Vaccination | 1 | 2022 | 189 | 0.050 |
Why?
|
| Ambulatory Care Facilities | 1 | 2021 | 91 | 0.040 |
Why?
|
| Artificial Intelligence | 1 | 2022 | 159 | 0.040 |
Why?
|
| Serologic Tests | 1 | 2020 | 46 | 0.040 |
Why?
|
| Cluster Analysis | 1 | 2020 | 219 | 0.040 |
Why?
|
| Alcohol Drinking | 1 | 2006 | 805 | 0.040 |
Why?
|
| Sexual Behavior | 1 | 2021 | 183 | 0.040 |
Why?
|
| Community-Acquired Infections | 1 | 2019 | 46 | 0.040 |
Why?
|
| Survivors | 1 | 2021 | 256 | 0.040 |
Why?
|
| Hospitals | 1 | 2021 | 265 | 0.040 |
Why?
|
| Confidentiality | 1 | 2019 | 62 | 0.040 |
Why?
|
| Health Promotion | 1 | 2023 | 407 | 0.040 |
Why?
|
| Veterans | 1 | 2006 | 904 | 0.040 |
Why?
|
| Databases, Factual | 1 | 2021 | 622 | 0.040 |
Why?
|
| Cost of Illness | 1 | 2019 | 206 | 0.040 |
Why?
|
| Sex Factors | 1 | 2020 | 1266 | 0.040 |
Why?
|
| Heterosexuality | 1 | 2016 | 17 | 0.030 |
Why?
|
| Canada | 1 | 2017 | 267 | 0.030 |
Why?
|
| Delivery of Health Care | 1 | 2021 | 445 | 0.030 |
Why?
|
| Aging | 1 | 2022 | 911 | 0.030 |
Why?
|
| Research Design | 1 | 2019 | 729 | 0.030 |
Why?
|
| Animals | 1 | 2012 | 20881 | 0.030 |
Why?
|
| Surveys and Questionnaires | 1 | 2021 | 2800 | 0.030 |
Why?
|
| Infant | 1 | 2019 | 2891 | 0.030 |
Why?
|
| Child, Preschool | 1 | 2019 | 3187 | 0.030 |
Why?
|
| Medical Audit | 1 | 2006 | 44 | 0.020 |
Why?
|